Vera Therapeutics, Inc. (VERA)

35,23 +0,34 (+0,97%) Alla chiusura: 04:00PM EDT

Vera Therapeutics, Inc.

8000 Marina Boulevard
Suite 120
Brisbane, CA 94005
United States
650 770 0077
https://veratx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 55

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Marshall W. Fordyce M.D.	Founder, President, CEO & Director	910,14k	N/D	1975
Mr. Sean P. Grant M.B.A.	Chief Financial Officer	642k	N/D	1985
Mr. Joseph R. Young M.B.A.	Senior VP of Finance & Chief Accounting Officer	N/D	N/D	1973
Mr. Julien E. Capers J.D.	VP & Head of Legal	N/D	N/D	N/D
Ms. Kelly Rauber	VP & Head of Human Resources	N/D	N/D	N/D
Mr. Tom Doan	Senior Vice President of Development Operations	N/D	N/D	1972
Ms. Lauren Frenz	Chief Business Officer	N/D	N/D	1985
Dr. Neeraj Pakala M.B.A., Ph.D.	Senior VP and Head of Product Development & Manufacturing	N/D	N/D	N/D
Dr. Kerry Cooper M.D.	Senior Vice President of Medical Affairs	N/D	N/D	N/D
Dr. Robert M. Brenner M.D.	Chief Medical Officer	N/D	N/D	1968

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Governance aziendale

L'ISS Governance QualityScore di Vera Therapeutics, Inc. al 1 giugno 2024 è 8. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.